Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma

References

• International Agency for Research on Cancer. WHO. Estimated number of indience cases and deaths, both sexes, worlwide(top 10 cancer sites)in 2020. cited Sep 8, 2021]. Available from 2021 Sep 8: http://gco.iarc.fr/today/online-analysis-multibars?mode=cancer&mode_population=continents&population=900&sex=0&cancer=7&type=0&statistic=0&prevalence=0&color_palette=default.
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.
   PubMed Web of Science ®Google Scholar
• Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245.
   Web of Science ®Google Scholar
• Raoul JL, Kudo M, Finn RS, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. Cancer Treat Rev. 2018;68:16–24.
   PubMed Web of Science ®Google Scholar
• Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, et al. Hepatocellular carcinoma: a comprehensive review of biomarkers, clinical aspects, and therapy. Asian Pac J Cancer Prev. 2017;18(4):863–872.
   PubMedGoogle Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359(4): 378–390. 2008.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology(nccn guidelines®),hepatobiliary cancers, version 5. 2020. cited Sep 8, 2021]. Available from 2021 Sep 8: www.nccn.org. (accessed 2021 Sep 8).
   Google Scholar
• Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across child-pugh subgroups: the GIDEON study. J Hepatol. 2016;65(6):1140–1147.
   PubMed Web of Science ®Google Scholar
• Yada M, Masumoto A, Motomura K, et al. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol. 2014;20(35):12581–12587.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–566.
   PubMed Web of Science ®Google Scholar
• Nakano M, Tanaka M, Kuromatsu R, et al. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Med. 2015;4(12):1836–1843.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–1354.
   PubMed Web of Science ®Google Scholar
• Shen A, Tang C, Wang Y, et al. A systematic review of sorafenib in child-pugh a patients with unresectable hepatocellular carcinoma. J Clin Gastroenterol. 2013;47(10):871–880.
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–829.
   PubMed Web of Science ®Google Scholar
• Shuster A, Huynh TJ, Rajan DK, et al. Response evaluation criteria in solid tumors (recist) criteria are superior to european association for study of the liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer. J Vasc Interv Radiol. 2013;24(6):805–812.
   PubMed Web of Science ®Google Scholar
• Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118(1):16–22.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li A, Sun S, et al. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation? J BUON. 2014;19(2):398–405.
   PubMed Web of Science ®Google Scholar
• Bargellini I, Bozzi E, Campani D, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82(5):212–218.
   Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
   PubMed Web of Science ®Google Scholar
• Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147–156.
   PubMed Web of Science ®Google Scholar
• Di Tommaso L, Spadaccini M, Donadon M, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol. 2019;25(40):6041–6052.
   PubMed Web of Science ®Google Scholar
• Su YH, Kim AK, Jain S. Liquid biopsies for hepatocellular carcinoma. Transl Res. 2018;201:84–97.
   PubMed Web of Science ®Google Scholar
• De Stefano F, Chacon E, Turcios L, et al. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50(11):1115–1123.
   PubMedGoogle Scholar
• Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: are we getting there? World J Gastroenterol. 2015;21(36):10336–10347.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gao Q, Pei L, et al. Current status and future prospects of biomarkers in the diagnosis of hepatocellular carcinoma. Int J Biol Markers. 2017;32(4):e361–e369.
   PubMed Web of Science ®Google Scholar
• Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol. 2018;24(35):3974–3979.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Bmj-Brit Med J. 2015;2(350):g7647. ** Our study was performed according to this guidline.
   Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Ishigami M, Ishizu Y, et al. Early clinical response after 2 weeks of sorafenib therapy predicts outcomes and anti-tumor response in patients with advanced hepatocellular carcinoma. PLoS One. 2015;10(9):e0138776.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim BK, Kim SU, et al. Early alpha-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. J Hepatocell Carcinoma. 2015;2:39–47.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao Y, Jia J, et al. The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib combined with transarterial chemoembolization. Sci Rep. 2016;2(6);19851.
   Google Scholar
• Nakazawa T, Hidaka H, Takada J, et al. Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2013;25(6):683–689.
   PubMed Web of Science ®Google Scholar
• Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57(1):101–107.
   PubMed Web of Science ®Google Scholar
• Sanchez AIP, Roces LV, Garcia IZ, et al. Value of alpha-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett. 2018;15(6):8863–8870.
   PubMed Web of Science ®Google Scholar
• Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116(19):4590–4596.
   PubMed Web of Science ®Google Scholar
• Sohn W, Paik YH, Cho JY, et al. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol. 2015;62(5):1112–1121.
   PubMed Web of Science ®Google Scholar
• Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16(9):1270–1279.
   PubMed Web of Science ®Google Scholar
• El Shorbagy S, abuTaleb F, Labib HA, et al. Prognostic significance of VEGF and HIF-1 α in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination. J Gastrointest Cancer. 2021;52(1):269–279.
   PubMed Web of Science ®Google Scholar
• Godin C, Bodeau S, Saidak Z, et al. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma. Oncol Rep. 2019;41(3):2041–2050.
   PubMed Web of Science ®Google Scholar
• Goyal L, Zheng H, Abrams TA, et al. A phase II and biomarker study of sorafenib combined with modified folfox in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2019;25(1):80–89.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–2300.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Asahina Y, Matsuda S, et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer. 2014;120(2):229–237.
   PubMed Web of Science ®Google Scholar
• Zhu A, Kang Y, Rosmorduc O, et al. Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the search trial. Clin Cancer Res. 2016;22(19):4870–4879.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Blanc JF, Miles S, et al. Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma. Oncologist. 2017;22(7):780–e765.
   PubMed Web of Science ®Google Scholar
• Adachi T, Nouso K, Miyahara K, et al. Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol. 2019;34(6):1081–1087.
   PubMed Web of Science ®Google Scholar
• Miyahara K, Nouso K, Tomoda T, et al. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(11):1604–1611.
   PubMed Web of Science ®Google Scholar
• Miyahara K, Nouso K, Morimoto Y, et al. Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. Br J Cancer. 2013;109(8):2072–2078.
   PubMed Web of Science ®Google Scholar
• Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology. 2012;83(4):192–200.
   PubMed Web of Science ®Google Scholar
• Kondo M, Numata K, Hara K, et al. Treatment of advanced hepatocellular carcinoma after failure of sorafenib treatment: subsequent or additional treatment interventions contribute to prolonged survival postprogression. Gastroenterol Res Pract. 2017;2017:5728946.
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in alpha-fetoprotein, but not des-gamma-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011;81(3–4):251–258.
   PubMed Web of Science ®Google Scholar
• Miyahara K, Nouso K, Morimoto Y, et al. Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res. 2013;43(10):1064–1070.
   PubMed Web of Science ®Google Scholar
• Nakano M, Tanaka M, Kuromatsu R, et al. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology. 2013;84(2):108–114.
   PubMed Web of Science ®Google Scholar
• Ueshima K, Kudo M, Takita M, et al. Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis. 2011;29(3):321–325.
   PubMed Web of Science ®Google Scholar
• Wang J, Yin Y, Huang A, et al. Diagnostic value of des-gamma-carboxy prothrombin for recurrent HCC in patients undergoing precautionary sorafenib treatment after curative hepatectomy. Acta Med Mediterr. 2020;36:1047–1053.
   Web of Science ®Google Scholar
• Afshar M, Fletcher P, Bardoli AD, et al. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget. 2018;9(24):16988–16995.
   PubMedGoogle Scholar
• Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67(5):999–1008.
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Dadduzio V, Rovesti G, et al. Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine (Baltimore). 2020;99(22):e19958.
   PubMed Web of Science ®Google Scholar
• Conroy G, Salleron J, Belle A, et al. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget. 2017;8(56):95853–95864.
   PubMedGoogle Scholar
• da Fonseca LG, Barroso-Sousa R, Bento Ada S, et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31(11):264.
   PubMed Web of Science ®Google Scholar
• Diaz-Beveridge R, Bruixola G, Lorente D, et al. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol. 2018;20(3):322–329.
   PubMed Web of Science ®Google Scholar
• Gardini AC, Scarpi E, Faloppi L, et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016;7(41):67142–67149.
   PubMedGoogle Scholar
• HaHa Y, Mohamed Ali MA, Petersen M, et al. ELymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. Hepatol Int. 2020;14(5):776–787.
   PubMed Web of Science ®Google Scholar
• Hong YM, Yoon KT, Hwang TH, et al. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2019;31(10):1250–1255.
   PubMed Web of Science ®Google Scholar
• Howell JA, Pinato DJ, Ramaswami R, et al. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget. 2017;8(22):36161–36170.
   PubMedGoogle Scholar
• Katayama K, Kiyota R, Imai T, et al. Factors affecting therapeutic effects in 17 patients with advanced hepatocellular carcinoma who were treated with sorafenib for more than 12 months. Case Rep Oncol. 2018;11(3):711–720.
   PubMed Web of Science ®Google Scholar
• Li X, Chen ZH, Ma XK, et al. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumor Biol. 2014;35(11):11057–11063.
   PubMedGoogle Scholar
• Li X, Chen ZH, Xing YF, et al. Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumor Biol. 2015;36(4):2263–2269.
   PubMedGoogle Scholar
• Lué A, Serrano MT, Bustamante FJ, et al. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget. 2017;8(61):103077–103086.
   PubMedGoogle Scholar
• Nakano M, Kuromatsu R, Niizeki T, et al. Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. Esmo Open. 2021;6(1):100020.
   PubMed Web of Science ®Google Scholar
• Wei K, Wang M, Zhang W, et al. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 2014;31(6):969.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. Med Oncol. 2015;32(4):107.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yan ZP, Hou ZH, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus sorafenib. Front Mol Biosci. 2021;28(8):624366.
   Google Scholar
• Zheng YB, Zhao W, Liu B, et al. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev. 2013;14(9):5527–5531.
   PubMedGoogle Scholar
• Zhu Z, Xu L, Zhuang L, et al. Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma. Onco Targets Ther. 2018;11:6731–6740.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim SS, Nam JS, et al. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with Hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. Cytokine. 2017;95:118–125.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Yamashita T, Terashima T, et al. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. BMC Cancer. 2017;17(1):870.
   PubMedGoogle Scholar
• Iida-Ueno A, Enomoto M, Uchida-Kobayashi S, et al. Changes in plasma interleukin-8 and tumor necrosis factor-alpha levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018;82(5):857–864.
   PubMed Web of Science ®Google Scholar
• Shao Y, Hsu C, Huang C, et al. Use of plasma angiogenesis-related factors to investigate the association of interleukin 8 and interleukin 6 levels with efficacy of sorafenib-based antiangiogenic therapy in patients with advanced hepatocellular carcinoma (HCC). J clin oncol. 2016;29:199.
   Google Scholar
• Casadei Gardini A, Marisi G, Dadduzio V, et al. Association of NOS3 and ANGPT2 Gene Polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective innovate study. Clin Cancer Res. 2020;26(17):4485–4493.
   PubMed Web of Science ®Google Scholar
• Gardini AC, Marisi G, Faloppi L, et al. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016;7(19):27989–27999.
   Google Scholar
• Marisi G, Petracci E, Raimondi F, et al. ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib. Cancers (Basel). 2019;11(7):1023.
   Web of Science ®Google Scholar
• Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135(5):1247–1256.
   PubMed Web of Science ®Google Scholar
• Tandia M, Mhiri A, Paule B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer Chemother Pharmacol. 2017;79(4):759–766.
   PubMed Web of Science ®Google Scholar
• Zheng YB, Zhan MX, Zhao W, et al. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Med Oncol. 2014;31(10):209.
   PubMed Web of Science ®Google Scholar
• Alunni-Fabbroni M, Ronsch K, Huber T, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med. 2019;17(1):328.
   PubMed Web of Science ®Google Scholar
• Oh CR, Kong SY, Im HS, et al. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. BMC Cancer. 2019;19(1):292.
   PubMedGoogle Scholar
• Kohno T, Morishita A, Iwama H, et al. Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. Oncol Lett. 2020;20(2):1727–1733.
   PubMed Web of Science ®Google Scholar
• Nishida N, Arizumi T, Hagiwara S, et al. MicroRNAs for the prediction of early response to sorafenib treatment in human hepatocellular carcinoma. Liver Cancer. 2017;6(2):113–125.
   PubMed Web of Science ®Google Scholar
• Stiuso P, Potenza N, Lombardi A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids. 2015;4:e233.
   PubMedGoogle Scholar
• Wang G, Zhao W, Wang H, et al. Exosomal mir-744 inhibits proliferation and sorafenib chemoresistance in hepatocellular carcinoma by targeting PAX2. Med Sci Monit. 2019;25:7209–7217.
   PubMed Web of Science ®Google Scholar
• Yoon EL, Yeon JE, Ko E, et al. An explorative analysis for the role of serum mir-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma. J Korean Med Sci. 2017;32(2):212–220.
   PubMed Web of Science ®Google Scholar
• Zhan G, Jiang H, Yang R, et al. miR-122 and miR-197 expressions in hepatic carcinoma patients before and after chemotherapy and their effect on patient prognosis. Am J Transl Res. 2021;13(6):6731–6737.
   PubMed Web of Science ®Google Scholar
• Faranda T, Grossi I, Manganelli M, et al. Differential expression profiling of long non-coding RNA GAS5 and miR-126-3p in human cancer cells in response to sorafenib. Sci Rep. 2019;9(1):9118.
   PubMedGoogle Scholar
• Masuda K, Ono A, Aikata H, et al. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol. 2018;53(1):107–118.
   PubMed Web of Science ®Google Scholar
• Orsi G, Tovoli F, Dadduzio V, et al. Prognostic role of blood eosinophil count in patients with sorafenib-treated hepatocellular carcinoma. Target Oncol. 2020;15(6):773–785.
   PubMed Web of Science ®Google Scholar
• Shao YY, Lin ZZ, Chen TJ, et al. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. Oncology. 2011;81(2):98–103.
   PubMed Web of Science ®Google Scholar
• Trevisani F, Garuti F, Neri A. Alpha-fetoprotein for diagnosis, prognosis, and transplant selection. Semin Liver Dis. 2019;39(2):163–177.
   PubMed Web of Science ®Google Scholar
• Berhane S, Fox R, Garcia-Finana M, et al. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer. 2019;121(2):117–124.
   PubMed Web of Science ®Google Scholar
• Xu XS, Qu K, Liu C, et al. Highlights for alpha-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol. 2012;18(48):7242–7250.
   PubMed Web of Science ®Google Scholar
• Takaki S, Fukuhara T, Mori N, et al. High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma. Mol Clin Oncol. 2020;12(1):60–68.
   PubMed Web of Science ®Google Scholar
• Labeur TA, Berhane S, Edeline J, et al. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int. 2020;40(1):215–228.
   PubMed Web of Science ®Google Scholar
• Edeline J, Blanc JF, Campillo-Gimenez B, et al. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a new application for the hepatoma arterial embolisation prognostic score. Eur J Cancer. 2017; Oxford, England: 1990;86:135–142.
   PubMed Web of Science ®Google Scholar
• Negri FV, Dal Bello B, Porta C, et al. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver Int. 2015;35(8):2001–2008.
   PubMed Web of Science ®Google Scholar
• Kanda T, Jiang X, Yokosuka O. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. World J Gastroenterol. 2014;20(28):9229–9236.
   PubMed Web of Science ®Google Scholar
• Bronte F, Bronte G, Cusenza S, et al. Targeted therapies in hepatocellular carcinoma. Curr Med Chem. 2014;21(8):966–974.
   PubMed Web of Science ®Google Scholar
• Pena C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res. 2010;16(19):4853–4863.
   PubMed Web of Science ®Google Scholar
• Ebos JML, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007;104(43):17069–17074.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Mori M, Sakamoto Y, et al. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest. 1999;103(3):341–345.
   PubMed Web of Science ®Google Scholar
• Lauren J, Gunji YJ, Alitalo K. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol. 1998;153(5):1333–1339.
   PubMed Web of Science ®Google Scholar
• Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Oncol Targets Ther. 2014;7:1927–1932.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
   PubMed Web of Science ®Google Scholar
• Torimura T, Ueno T, Kin M, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol. 2004;40(5):799–807.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45(12):1272–1282.
   PubMed Web of Science ®Google Scholar
• Murata K, Suzuki H, Okano H, et al. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36(1):161–170.
   PubMed Web of Science ®Google Scholar
• Chakladar J, Wong LM, Kuo SZ, et al. The liver microbiome is implicated in cancer prognosis and modulated by alcohol and Hepatitis B. Cancers (Basel). 2020;12(6):1642.
   Web of Science ®Google Scholar
• Liu LX, Gong Y, Zhang QL, et al. Prognostic roles of blood inflammatory markers in hepatocellular carcinoma patients taking sorafenib. a systematic review and meta-analysis. Front Oncol. 2020;9.
   Web of Science ®Google Scholar
• Mantovani A. The inflammation - cancer connection. FEBS J. 2018;285(4):638–640.
   PubMed Web of Science ®Google Scholar
• Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012;491(7423):259–263.
   PubMed Web of Science ®Google Scholar
• Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147(6):1233–1247.
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–527.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519–531.
   PubMed Web of Science ®Google Scholar
• Personeni N, Giordano L, Abbadessa G, et al. Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. Oncotarget. 2017;8(9):14408–14415.
   PubMedGoogle Scholar
• Li X, Chen ZH, Xing YF, et al. Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2015;36(4):2263–2269.
   PubMedGoogle Scholar
• Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904–910.
   PubMed Web of Science ®Google Scholar
• Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65(23):10794–10800.
   PubMed Web of Science ®Google Scholar
• Plante M, Rubin SC, Wong GY, et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994;73(7):1882–1888.
   PubMed Web of Science ®Google Scholar
• Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26(1):38–47.
   PubMed Web of Science ®Google Scholar
• Sun R, Jaruga B, Kulkarni S, et al. IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: regulation by SOCS3. Biochem Biophys Res Commun. 2005;338(4):1943–1949.
   PubMed Web of Science ®Google Scholar
• Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95(8):2630–2636.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–844.
   PubMed Web of Science ®Google Scholar
• Gacche RN. Compensatory angiogenesis and tumor refractoriness. Oncogenesis. 2015;4(6):e153.
   PubMedGoogle Scholar
• von Felden J, Garcia-Lezana T, Schulze K, et al. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020;69(11):2025–2034.
   PubMed Web of Science ®Google Scholar
• Wang Z, Duan J, Cai S, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 2019;5(5):696–702.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Nabet BY, Rizvi H, et al. Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clin Cancer Res. 2020;26(12):2849–2858.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129–3140.
   PubMed Web of Science ®Google Scholar
• Ziche M, Morbidelli L. Molecular regulation of tumour angiogenesis by nitric oxide. Eur Cytokine Netw. 2009;20(4):164–170.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001;98(5):2604–2609.
   PubMed Web of Science ®Google Scholar
• Yin CQ, Yuan CH, Qu Z, et al. Liquid biopsy of hepatocellular carcinoma: circulating tumor-derived biomarkers. Dis Markers. 2016;2016:1427849.
   PubMed Web of Science ®Google Scholar
• Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci. 2020;16(9):1551–1562.
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Chabner BA. Application of cell-free dna analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–1765.
   PubMed Web of Science ®Google Scholar
• Tokuhisa Y, Iizuka N, Sakaida I, et al. Circulating cell-free DNA as a predictive marker for distant metastasis of Hepatitis C virus-related hepatocellular carcinoma. Br J Cancer. 2007;97(10):1399–1403.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Shen S, Lin Y, Yuan X, et al. Biomarker microRNAs for diagnosis, prognosis and treatment of hepatocellular carcinoma: a functional survey and comparison. Sci Rep. 2016;6(1):38311.
   PubMedGoogle Scholar
• Kanthaje S, Makol A, Chakraborti A. Sorafenib response in hepatocellular carcinoma: microRNAs as tuning forks. Hepatol Res. 2018;48(1):5–14.
   PubMed Web of Science ®Google Scholar
• Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 2012;56(6):1371–1383.
   PubMed Web of Science ®Google Scholar
• Lou G, Song X, Yang F, et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8(1):122.
   PubMedGoogle Scholar
• Tsai WC, Hsu SD, Hsu CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122(8):2884–2897.
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Andersen JB, et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–3536.
   PubMed Web of Science ®Google Scholar
• Mao K, Zhang J, He C, et al. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett. 2014;352(2):245–252.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Takehara T, Hikita H, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 2010;52(5):698–704.
   PubMed Web of Science ®Google Scholar
• Fang X, Wang D, Pu K, et al. Diagnostic value of circulating lncRNAs as biomarkers of digestive system cancers: a systematic review and meta-analysis. Expert Rev Mol Diagn. 2020;20(10):1051–1062.
   PubMed Web of Science ®Google Scholar
• Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–1261.
   PubMed Web of Science ®Google Scholar
• Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncol. 2017;18(2):e101–e112.
   PubMed Web of Science ®Google Scholar
• Sansone V, Tovoli F, Casadei-Gardini A, et al. Comparison of prognostic scores in patients with hepatocellular carcinoma treated with sorafenib. Clin Transl Gastroenterol. 12(1): e00286. 2021.
   PubMed Web of Science ®Google Scholar
• Berhane S, Fox R, García-Fiñana M, et al. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer. 2019;121(2):117–124.
   PubMed Web of Science ®Google Scholar
• Choi GH, Han S, Shim JH, et al. Prognostic scoring models for patients undergoing sorafenib treatment for advanced stage hepatocellular carcinoma in real-life practice. Am J Clin Oncol. 2017;40(2):167–174.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Bucci L, Garuti F, et al. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology. 2018;67(5):1784–1796.
   PubMed Web of Science ®Google Scholar
• Caputo F, Dadduzio V, Tovoli F, et al. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS One. 2020;15(5):e0232449.
   PubMed Web of Science ®Google Scholar
• Di Costanzo GG, Casadei Gardini A, Marisi G, et al. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Target Oncol. 2017;12(6):795–803.
   PubMed Web of Science ®Google Scholar
• Granito A, Marinelli S, Negrini G, et al. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol. 2016;9(2):240–249.
   PubMed Web of Science ®Google Scholar
• Shin SY, Lee YJ. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib. Int J Clin Pharmacol Ther. 2013;51(11):837–846.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15(1):85–92.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li H, Bai W, et al. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: a multicenter clinical study of 606 HCC patients. Int J Cancer. 2016;139(4):928–937.
   PubMed Web of Science ®Google Scholar